Jun 2026 (Q2 FY26) — Aug 10, 2026
Alamar Biosciences Q2 FY26 — Strong Consumable Growth and Strategic Expansion
Read the full callAlamar Biosciences (ALMR) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
Alamar Biosciences earnings: last reported Mon, 10 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 29.4 | +82.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -46.0 | +3.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -13.2 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$27.42 +8.08% · +$2.05
Performance +24.6% YTD
YTD: $22 on 17 Apr 2026 → $27.42. High $38.13 (5 Oct 2026), low $19.09 (26 May 2026).
- Previous close
- $25.37
- 52-week range
- $19.09 – $38.13
Overview
- Symbol
- ALMR
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Alamar Biosciences earnings calls (ALMR)
Financials
What the filings say
Net profit, year on year: −88% (quarter to jun 2026 against jun 2025).
| Line item | Mar 2025 | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 13 | 16 | 26 | 29 |
| Operating profit | -9 | -8 | -12 | -14 |
| Operating margin | −65.3% | −49.0% | −47.4% | −46.0% |
| Profit before tax | -8 | -7 | -21 | -13 |
| Tax rate | — | — | −2.2% | 0.7% |
| Net profit | -8 | -7 | -21 | -13 |
| EPS ($ per share) | -0.68 | -0.62 | -1.74 | -0.22 |
Insider filings
46 filings between Apr 20, 2026 and Sep 14, 2026.
Open market
decisions to buy or sellPurchases
$8.00M
2 purchases by 2 insiders
Sales
None
No insider sold shares.
Compensation
not trading decisions- 7
- Award — granted as compensation
Also filed: 20 other filings, 17 conversions.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Naclerio Nicholas | $4.00M | — | Apr 20, 2026 |
| Illumina Innovation Fund II GP, L.L.C. | $4.00M | — | Apr 20, 2026 |
Latest filings (46)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 14, 2026 | Brottem John L. General Counsel | Award | 29,000 | $0 |
| Sep 1, 2026 | RAGUSA ROBERT P Director | Award | 5,686 | $0 |
| Apr 20, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Conversion | 6,881,410 | — |
| Apr 20, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Conversion | 1,605,645 | — |
| Apr 20, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Conversion | 1,922,329 | — |
| Apr 20, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Other | 185,163 | — |
| Apr 20, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Other | 6,881,410 | — |
| Apr 20, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Other | 1,605,645 | — |
| Apr 20, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Conversion | 185,163 | — |
| Apr 20, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Other | 1,922,329 | — |
| Apr 20, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Other | 185,163 | — |
| Apr 20, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Other | 6,881,410 | — |
| Apr 20, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Other | 1,605,645 | — |
| Apr 20, 2026 | Qiming Corporate GP VI, Ltd. 10% owner | Other | 1,922,329 | — |
| Apr 20, 2026 | Naclerio Nicholas Director | Conversion | 346,020 | — |
| Apr 20, 2026 | Chen Shiping Chief Operating Officer | Other | 722,885 | $0 |
| Apr 20, 2026 | Chen Shiping Chief Operating Officer | Award | 37,220 | $0 |
| Apr 20, 2026 | Naclerio Nicholas Director | Conversion | 271,782 | — |
| Apr 20, 2026 | Naclerio Nicholas Director | Purchase | 235,294 | $4.00M |
| Apr 20, 2026 | Naclerio Nicholas Director | Award | 5,686 | $0 |
| Apr 20, 2026 | McAnear Justin J. Chief Financial Officer | Award | 37,220 | $0 |
| Apr 20, 2026 | White Timothy Ogden President | Other | 454,583 | — |
| Apr 20, 2026 | White Timothy Ogden President | Other | 454,583 | — |
| Apr 20, 2026 | White Timothy Ogden President | Award | 37,220 | $0 |
| Apr 20, 2026 | Luo Yuling Chief Executive Officer | Conversion | 1,386,746 | — |
| Apr 20, 2026 | Luo Yuling Chief Executive Officer | Conversion | 364,268 | — |
| Apr 20, 2026 | Luo Yuling Chief Executive Officer | Other | 1,864,065 | — |
| Apr 20, 2026 | Luo Yuling Chief Executive Officer | Other | 1,864,065 | — |
| Apr 20, 2026 | Luo Yuling Chief Executive Officer | Award | 76,509 | $0 |
| Apr 20, 2026 | Luo Yuling Chief Executive Officer | Other | 1,224,152 | — |
| Apr 20, 2026 | Luo Yuling Chief Executive Officer | Other | 1,224,152 | — |
| Apr 20, 2026 | Chen Shiping Chief Operating Officer | Conversion | 320,511 | — |
| Apr 20, 2026 | Luo Yuling Chief Executive Officer | Conversion | 1,224,152 | — |
| Apr 20, 2026 | Illumina Innovation Fund II GP, L.L.C. 10% owner | Conversion | 4,588,364 | — |
| Apr 20, 2026 | Illumina Innovation Fund II GP, L.L.C. 10% owner | Conversion | 922,152 | — |
| Apr 20, 2026 | Illumina Innovation Fund II GP, L.L.C. 10% owner | Other | 5,510,516 | — |
| Apr 20, 2026 | Illumina Innovation Fund II GP, L.L.C. 10% owner | Other | 5,510,516 | — |
| Apr 20, 2026 | Illumina Innovation Fund II GP, L.L.C. 10% owner | Conversion | 346,020 | — |
| Apr 20, 2026 | Chen Shiping Chief Operating Officer | Conversion | 72,853 | — |
| Apr 20, 2026 | Chen Shiping Chief Operating Officer | Other | 722,885 | — |
| Apr 20, 2026 | Illumina Innovation Fund II GP, L.L.C. 10% owner | Conversion | 271,782 | — |
| Apr 20, 2026 | Illumina Innovation Fund II GP, L.L.C. 10% owner | Purchase | 235,294 | $4.00M |
| Apr 20, 2026 | Naclerio Nicholas Director | Conversion | 4,588,364 | — |
| Apr 20, 2026 | Naclerio Nicholas Director | Conversion | 922,152 | — |
| Apr 20, 2026 | Naclerio Nicholas Director | Other | 5,510,516 | — |
| Apr 20, 2026 | Naclerio Nicholas Director | Other | 5,510,516 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Alamar Biosciences, Inc.
Free account. Everything above stays public.
Write why you follow Alamar Biosciences, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading